The Effects of In-phase Bilateral Exercise on Cognitive and Motor Outcome Measures, in Patients with Progressive Multiple Sclerosis, a Randomized Control Trial.

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. MS, typical presents with progression of clinical symptoms which mainly include motor and cognitive impairment, as well as reduction of patients' quality of life. Exercise is an effective approach in the management of the symptoms in people with progressive MS. Previous studies in healthy and in people with MS, reported a close relationship between cognitive functions and upper limb performance. Since patients with progressive MS facing difficulties with performing complex exercises due to cognitive dysfunctions and given the close relationship between cognitive functions and manual dexterity, a reasonable question arises whether a type of upper limbs exercises with less cognitive demands will improve the information processing speed in people with progressive MS. The aim of the current study is to investigate the effects of in-phase bilateral upper limbs exercises on the information processing speed, in patients with progressive MS, given that in-phase bilateral movements needs less attentional load than the other types of bilateral coordination. The intervention protocol lasted for 12 consecutive weeks (30-60 minutes /session x 3 sessions/week) and included in-phase bilateral exercises of the upper limbs, adapted to different sports activities and to functional training. Results from the statistical analysis indicated improvement of the experimental group compared to the control group, on the information processing speed alongside with improvement of motor skills.

开始日期2023-10-02

申办/合作机构

Cyprus University of Technology

[+1]

NCT05911672 / Not yet recruitingN/AIIT

Testing and Evaluating the Collection of Patient Reported Outcomes In Cancer CarE Using Innovative Approaches: The ePROM Digital Health Tool

Patient Reported Outcome Measures (PROMs) are patients' reports of their symptom experience, quality of life and functionality. These measures are used as an endpoint to clinical trials but rarely integrated into routine cancer care. Moreover, they are resource intensive and prone to retrospective biases. PRICE project aims to develop and evaluate a digital health tool (ePROM), collecting PROMs at the clinic and additional Ecological Momentary Assessment (EMA) of PROMs using a mobile application. In addition it tests whether patients who are identified to have elevated pain, fatigue, and stress will benefit from an Ecological Momentary Intervention (EMI) based on Virtual Reality environments. EMA can overcome biases and barriers in PROM assessment whilst EMI can offer an easy and possibly cost-effective intervention until patients re-visit the clinic. The project can contribute to monitoring patient data and achieve viable health systems. It is also timely since digital health tools are considered the future of oncology care but often lack robustness in development and evaluation. Patients treated for cancer at the German Oncology Centre in Cyprus will be randomized into three conditions: (a) Full Intervention (patients who are prompted to use the EMI based on their EMA data; (b) Partial Intervention (patients who are prompted to use the EMI irrespective of their EMA data); (c) Control (patients who only provide their EMA without an EMI). A dissemination strategy will ensure findings and innovation are available to the public, clinicians, students and policy-makers.

开始日期2023-06-20

申办/合作机构

Cyprus University of Technology

[+1]

NCT05367947 / CompletedN/AIIT

Investigation of In-phase Bilateral Exercise Effects on Corticospinal Plasticity in Relapsing Remitting Multiple Sclerosis: a Registered Report Single-case Concurrent Multiple Baseline Design Across Five Subjects

Relapsing-remitting multiple sclerosis (RRMS) is associated with changes of the corticospinal tract integrity, which is quantified by means of corticospinal plasticity. Several factors, such as exercise and interlimb coordination can influence such corticospinal plasticity. Previous work in healthy and in stroke participants showed that the greatest improvement of corticospinal plasticity occurred during in-phase bilateral arm exercises. Here, the investigators propose a concurrent multiple baseline design study which has the advantage to verify the cause-effect inference by the staggered duration through separate baseline phases. The proposed study includes five people with RRMS, who will follow an intervention protocol which includes in-phase bilateral movements of the upper limbs, adapted to different sports activities and to functional training. The aim of the study is to investigate the effects of in-phase bilateral exercises on corticospinal plasticity and on clinical measures, using transcranial magnetic stimulation and standardized clinical assessment. To meet quality standards, the present study has been designed and will be conducted according to the "What Works Clearinghouse" criteria for single case studies.

开始日期2023-03-10

申办/合作机构

Cyprus University of Technology

[+1]

100 项与 Cyprus University of Technology 相关的临床结果

登录后查看更多信息

0 项与 Cyprus University of Technology 相关的专利（医药）

登录后查看更多信息

1,734

项与 Cyprus University of Technology 相关的文献（医药）

2025-02-01·Intensive and Critical Care Nursing

Music as healing in ICU survivors: The road ahead in seeking the right tone

作者: van Mol, Margo ; Mpouzika, Meropi

2024-12-01·BIORESOURCE TECHNOLOGY

Enhanced recovery of waste-born nutrients from sewage sludge ash and fish meal through fungal treatment: Mechanistic insights and impact of heavy metals

Article

作者: Zielinski, Jakub ; Galanty, Agnieszka ; Michellin Kiruba N, Jennifer ; Dobrowolska-Iwanek, Justyna ; Winiarski, Julius ; Fotopoulos, Vasileios ; Saeid, Agnieszka

This study investigates the potential of Talaromyces adpressus TCPF to enhance phosphate recovery and nutrient bioavailability from sewage sludge ash (SSA) and fish meal (FM) through co-fermentation. The fungal treatment was found to significantly increase phosphate recovery, achieving up to 16 % efficiency, especially at a 10 g/L waste concentration. The key mechanism behind this enhancement is the production of low molecular weight organic acids (LMWOAs), which played a crucial role in solubilizing nutrients while also mitigating the negative effects of heavy metals like lead and cadmium. Spectroscopic analyses confirmed substantial acid-based leaching and biomineralization processes, with over 70 % of phosphorus successfully bioleached from metal-treated waste. These findings underscore the effectiveness of fungal treatments in transforming waste substrates into valuable bio-organic fertilizers. Fungal treatment boosts phosphate recovery, even in the presence of heavy metals, by employing processes such as bioweathering, bioprecipitation, biocorrosion, and bioleaching.

2024-09-01·SLEEP MEDICINE

Restless leg syndrome in systemic lupus erythematosus: Associations with disease activity, quality of life and depression

Article

作者: Parperis, Konstantinos ; Constantinou, Argyris ; Psarelis, Savvas ; Bargiotas, Panagiotis ; Christophi, Costas A ; Philippou, Sofia

OBJECTIVES:

The aim of this study was to determine the prevalence of restless leg syndrome (RLS) among patients with SLE, describe their clinical characteristics, examine its impact on health-related quality of life (HRQoL), and evaluate its association with depression.

METHODS:

A total of 124 SLE patients were recruited, with data on demographics, and clinical features collected. RLS diagnosis was based on the international RLS study group criteria, while depression was assessed by the patient health questionnaire. HRQoL was assessed by a disease-specific validated questionnaire, the LupusQoL, pain intensity was examined through the pain visual analogue scale, and disease activity was evaluated via the patient global assessment. These variables were compared between SLE patients with RLS and without RLS using t-tests or Wilcoxon and the chi-square test of independence for categorical variables. A p-value ≤0.05 was considered statistically significant.

RESULTS:

Among the SLE patients (mean age 48, 87.1 % women), 32 % had RLS. The SLE patients with RLS were found to have a longer delay in diagnosis (1 vs 0.5 years; p = 0.019) and were less likely to be employed (65 % vs 45 %, p = 0.040) compared to non-RLS patients. In addition, RLS patients were more likely to have coexisting Major Depressive Disorder (MDD) (p = 0.019), higher levels of pain (p = 0.006) and disease activity based on patient global assessment (p = 0.014). Further, most of the domains of LupusQoL were significantly lower in the RLS patients group suggesting a worse HRQoL.

CONCLUSION:

RLS was present in one-third of the SLE cohort, significantly impairing HRQoL and correlating with depression, higher pain, and increased disease activity. These findings underscore the importance of early RLS detection and management in SLE patients.

项与 Cyprus University of Technology 相关的新闻（医药）

2024-06-17

·PRNewswire

Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for Services to Healthcare Innovation and Delivery

Ground-breaking discoveries on the characteristics of RNA epigenetics unveiled novel targets to treat diseases CAMBRIDGE, England, June 17, 2024 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, is delighted to announce that its Founder & Director and Professor of Cancer Biology, University of Cambridge, UK, Tony Kouzarides, PhD, FMedSci, FRS, will be honored with a Knighthood for his global impact on disease treatment. Professor Kouzarides, a world leading cancer biologist with a career spanning over 25 years, will be awarded the knighthood at the King's Birthday Honors, 2024, Investiture ceremony. Professor Kouzarides has been dedicated to the conversion of science into patient benefit throughout his career. STORM Therapeutics was spun out from the University of Cambridge in 2015 by Professor Kouzarides and his colleague Professor Eric Miska, following their groundbreaking work in RNA epigenetics. Professor Kouzarides and his research group identified the importance of RNA modifications during the development of cancer, opening the pathway for STORM to develop first-in-class drugs targeting this new mechanism. STORM's platform, eliciting cellular reprogramming through RNA modification, has potential beyond cancer in areas including neurodegenerative diseases, inflammation and infectious diseases. Professor Tony Kouzarides, Founder & Director of STORM Therapeutics, said: "I am honored to receive this award, which reinforces the importance of translating basic research into therapies by engaging academic researchers with healthcare businesses. STORM Therapeutics represents a shining example of this principle." Jerry McMahon, Chief Executive Officer of STORM Therapeutics, commented: "STORM is delighted to see Tony recognized nationally as a pioneer in the field of cellular reprogramming through RNA modification. Receiving this honor from the King is the pinnacle of a tremendous and productive career. Tony's commitment, focus and dedication has been unwavering, and we look forward to continuing to work with him as STORM's programs advance into the clinic as effective treatments for patients." In addition to his role at STORM, Professor Kouzarides is Professor of Cancer Biology at the University of Cambridge and a Senior Group Leader at the university's Gurdon Institute, specializing in developmental biology and cancer biology. He is also the Director and Co-Founder of the Milner Therapeutics Institute at the University of Cambridge, which focuses on building scientific collaborations to transform therapies. Professor Kouzarides also has his own laboratory in Cambridge, The TK LAB and has been studying epigenetic modifications for many years, starting with the identification of the first human enzymes to modify chromatin in 1996. His lab has identified and characterized many chromatin modification pathways and showed their involvement in cancer. The lab is now investigating the functions of mRNA modifications and their connections to cancer. In close collaboration with STORM Therapeutics, The Kouzarides Lab is targeting RNA modification pathways with small molecule inhibitors, to develop drugs against cancer and other diseases. Professor Kouzarides is also the Founder and Director of Cambridge Gravity, an organization for the promotion of science at the University of Cambridge. He is Founder and Patron of the Spanish cancer charity Vencer el Cancer ("Conquer Cancer"). Professor Kouzarides is Co-Founder and ex-Director of antibodies and reagents company Abcam, which was sold to the Danaher Corporation for US$5.7 billion (£4.5bn) in 2023. He was also Co-Founder and ex-Director of Chroma Therapeutics, a drug discovery company based in Oxford. Professor Kouzarides is an elected member of the European Molecular Laboratory Organization (EMBO), fellow of the British Academy of Medical Sciences (FMedSci), fellow of the Royal Society (FRS), fellow of the American Academy of Arts and Sciences (AAAS) and fellow of the Cyprus Academy of Sciences, Letters and Arts. He has also been awarded the Bodossaki Foundation prize in Biology, the Wellcome Trust Award for Research in Biochemistry Related to Medicine, the Tenovus Medal, the Bijvoet Medal, the Biochemical Society Novartis Medal and Prize, the Heinrich Wieland Prize, the Cyprus Excellence in Science Award and the Nemitsas Prize. Find out more about Professor Kouzarides on his Wikipedia page, here. NOTES TO EDITORS About STORM Therapeutics STORM Therapeutics is a clinical-stage biotechnology company pioneering cellular reprogramming through RNA modifications to treat disease. Its world leading understanding of RNA modifying enzymes (RME) has led to the discovery of breakthrough small molecule drugs that precisely reprogram cells through RNA biology for the treatment of cancer, inflammation, viruses and CNS diseases. STORM's lead product, STC-15, is the first RNA modifying enzyme inhibitor to enter human clinical development. STC-15 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors, establishing a data set allowing development in future clinical studies. Preclinical data have revealed that METTL3 inhibition stimulates immune cells and activates interferon pathways, leading to the destruction of tumor cells. Additional preclinical studies have demonstrated enhanced anti-tumor properties in combination with checkpoint inhibitors, supporting clinical development in tumor types where an augmented immune response may result in anti-cancer activity. STORM is building on its first-mover advantage by positioning additional RME inhibitor programs to advance into IND-track activities in 2024. STORM is seeking partners to collaborate and accelerate development of these novel drugs for disease applications outside of oncology. STORM's specialist healthcare investors include M Ventures, Pfizer Ventures, Taiho Ventures LLC, Seroba Life Sciences, Cambridge Innovation Capital Limited, IP Group plc, UTokyo Innovation Platform Co., Ltd. and the Fast Track Initiative (FTI). For more information, please visit . About STC-15 STORM's lead product, STC-15, is the first RME inhibitor to enter human clinical evaluation. This agent is an oral small molecule that inhibits METTL3, an RNA methyltransferase implicated in oncology and other diseases. Certain RNA methyltransferases are important regulators of RNA sensing and innate immune activation and, as such, represent novel immune-regulatory targets. STC-15 has also been shown preclinically to inhibit tumor growth through mechanisms involving anti-cancer immune responses, such as changes in interferon signaling and synergy with T cell checkpoint blockade. STORM is studying the safety and pharmacology of STC-15 in a Phase 1 clinical study in patients with solid tumors. Details of the study can be found on clinicaltrials.gov under the identifier NCT05584111. SOURCE STORM Therapeutics

临床1期

2022-11-02

·PRNewswire

CYENS Centre of Excellence presents at BioJapan / Regenerative Medicine Japan / healthTECH expo in Japan

NICOSIA, Cyprus, Nov. 2, 2022 /PRNewswire/ -- CYENS researchers Dr Christos Ioannou and Prof. Marios Avraamides participated the healthTECH expo in Yokohama, Japan on 12-14 October 2022 to present their respective projects, TONE and PULSEVR. The team is looking to engage with the Japanese industry to create synergies and collaborations. About TONE Continue Reading TONE Project - Using musculo-postural biofeedback in virtual reality for pain management in musicians." TONE is a digital biofeedback mirror tool developed by Dr Ioannou. The purpose of this tool is to prevent, diagnose and rehabilitate musculoskeletal disorders, caused by repetitive movements during work. Such task-specific disorders often develop in musicians and athletes. The biofeedback mirror tool uses motion tracking and electromyography sensors to display full-body musculo-postural feedback that simulates the movement of the user in real-time. The mirror tool provides corrective feedback to help users overcome work-related musculoskeletal disorders. "Imagine a mirror showing you what your posture and muscles are doing while you are playing an instrument or exercising. If something is wrong, you will know immediately and would be able to correct yourself. This means avoidance of injuries caused by repetitive actions or a relief from pain caused by musculoskeletal imbalances. Our tool gives an opportunity to any user to observe in real time how specific activities affect their own body", says Dr Ioannou. About PULSEVR PULSEVR, developed by Prof. Avraamides with SilverSky Ltd., is a Virtual Reality (VR) application that aims to treat Public Speaking Anxiety (PSA). Stage fright or fear of public speaking is often accompanied by a variety of physical and emotional reactions that pose a threat to mental health. PULSEVR implements interventions from Clinical and Cognitive Psychology and is part of a larger suite of VR apps that combine VR with eye-tracking and wearable sensors to treat conditions relating to anxiety. "PULSEVR is quite different from any other app in this field as it does not rely on desensitisation. We know from research that this doesn't work well in the long term. PULSE offers something that actually works", says Prof. Avraamides. CYENS Centre of Excellence is a joint venture of three public universities of Cyprus - University of Cyprus, Cyprus University of Technology, and Open University of Cyprus, the Municipality of Nicosia, and two renowned international partners, Max Planck Institute for Informatics, Germany, and, University College London, United Kingdom. CYENS is funded by the EU's Horizon 2020 and the Government of the Republic of Cyprus. For more information visit CONTACT: Andreas Psaltis, Partnerships Manager email: [email protected], +357 2274757 Logo - Photo - SOURCE CYENS Centre of Excellence